

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

L Number	Hits	Search Text	DB	Time stamp
1	385	Phosphodiesterase SAME antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:28
7	36	(Phosphodiesterase SAME antibody) and PDE1\$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:36
17	17		USPAT; US-PGPUB; EPO	2003/06/24 16:35
21	2	(Phosphodiesterase SAME antibody) and PDE11A\$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:40
27	10	PDE11A\$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:40
33	25	(US-6416991-\$ or US-6100037-\$ or US-6080548-\$ or US-6037119-\$ or US-6015677-\$ or US-5955583-\$ or US-5932423-\$ or US-5922595-\$ or US-5776752-\$ or US-5652131-\$ or US-5389527-\$ or US-5580771-\$).did. or (US-20030022282-\$ or US-20030061625-\$ or US-20030092156-\$ or US-20030054992-\$ or US-20020103120-\$ or US-20020115176-\$).did. or (EP-1018559-\$ or EP-1085089-\$ or EP-1085092-\$ or EP-1211313-\$).did. or (JP-2002360119-\$ or JP-2001136987-\$).did. or (EP-1211313-\$).did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:41
39	18	((US-6416991-\$ or US-6100037-\$ or US-6080548-\$ or US-6037119-\$ or US-6015677-\$ or US-5955583-\$ or US-5932423-\$ or US-5922595-\$ or US-5776752-\$ or US-5652131-\$ or US-5389527-\$ or US-5580771-\$).did. or (US-20030022282-\$ or US-20030061625-\$ or US-20030092156-\$ or US-20030054992-\$ or US-20020103120-\$ or US-20020115176-\$).did. or (EP-1018559-\$ or EP-1085089-\$ or EP-1085092-\$ or EP-1211313-\$).did. or (JP-2002360119-\$ or JP-2001136987-\$).did. or (EP-1211313-\$).did.) and antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:43
57	2	("6416991").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:44
63	2	("6100037").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/24 16:44
-	15	fidock NEAR mark	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 16:06
-	78	Phillips NEAR stephen	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 16:06
-	7	(Phillips NEAR stephen) and PDE\$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/23 16:07

(FILE 'HOME' ENTERED AT 16:51:16 ON 24 JUN 2003)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICINF' ENTERED
AT 16:51:25 ON 24 JUN 2003

L1 62816 S PHOSPHODIESTERASE?
L2 591 S L1 AND PDE1? OR PDEXV
L3 242 DUP REM L2 (349 DUPLICATES REMOVED)
L4 17 S L3 AND PDE11?
L5 17 SORT L4 PY
L6 1 S L1 AND PDEXV

=> d an ti so au ab pi l6

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 2001:207980 CAPLUS

DN 134:248839

TI Protein and cDNA sequences of a novel human cyclic nucleotide
phosphodiesterase PDEXV (PDE11A3) and uses thereof in
therapy and drug screening

SO Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW

IN Fidock, Mark David; Robas, Nicola Melanie

AB This invention provides protein and cDNA sequences for a newly identified
human cyclic nucleotide **phosphodiesterase**, designated
PDEXV (PDE11A3), which is believed to be a truncated version of
PDE11A1. The invention further relates to methods for utilizing
PDEXV in drug screening assays and in therapy directed against
diseases assocd. with inappropriate **PDEXV** activity or levels.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
PI EP 1085089	A2	20010321	EP 2000-307981	20000914

EP 1085089	A3	20010509		
------------	----	----------	--	--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2001136987	A2	20010522	JP 2000-279032	20000914
---------------	----	----------	----------------	----------

L9 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:472943 CAPLUS
 DN 135:73345
 TI **Phosphodiesterase PDE11A splice variants from human and rat**
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 IN Omori, Kenji; Yuasa, Keizo; Kotera, Jun; Oda, Kotomi; Michibata, Hideo
 AB Cyclic nucleotide **phosphodiesterase 11A (PDE11A)** splice variants from human and rat, their cDNAs, recombinant expression, antibodies, and use in screening of inhibitors, are disclosed. CDNAs encoding a novel **phosphodiesterase, phosphodiesterase 11A (PDE11A)**, were isolated by a combination of reverse transcriptase-polymerase chain reaction using degenerate oligonucleotide primers and rapid amplification of cDNA ends. Their catalytic domain was identical to that of **PDE11A1** (490 amino acids) reported during the course of this study. However, the cDNAs we isolated had N termini distinct from **PDE11A1**, indicating two novel N-terminal variants of **PDE11A**. **PDE11A3** cDNA encoded a 684-amino acid protein including one complete and one incomplete GAF domain in the N-terminal region. **PDE11A4** was composed of 934 amino acids including two complete GAF domains and shared 630 C-terminal amino acids with **PDE11A3** but had a distinct N terminus contg. the putative phosphorylation sites for cAMP- and cGMP-dependent protein kinases. **PDE11A3** transcripts were specifically expressed in testis, whereas **PDE11A4** transcripts were particularly abundant in prostate. Recombinant **PDE11A4** expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 3.0 and 1.4 μM , resp., and the Vmax value with cAMP was almost twice that with cGMP. Although **PDE11A3** showed the same Km values as **PDE11A4**, the relative Vmax values of **PDE11A3** were approx. one-sixth of those of **PDE11A4**. **PDE11A4**, but not **PDE11A3**, was phosphorylated by both cAMP- and cGMP-dependent protein kinases in vitro. Thus, the **PDE11A** gene undergoes tissue-specific alternative splicing that generates structurally and functionally distinct gene products. **PDE11A4** is sensitive to dipyrindamole, with an IC50 of 0.36 and 0.34 μM , for cAMP and cGMP, and to zaprinast, with an IC50 of 18 and 11 μM for cAMP and cGMP. **PDE11A3** demonstrated similar pattern of inhibitor sensitivity. Rat homologs were also cloned.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001046436	A1	20010628	WO 2000-JP9118	20001222
W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
JP 2001178467	A2	20010703	JP 1999-364866	19991222
JP 2001340084	A2	20011211	JP 2000-163875	20000601

L9 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:207980 CAPLUS
 DN 134:248839
 TI Protein and cDNA sequences of a novel human cyclic nucleotide
 phosphodiesterase PDEXV (PDE11A3) and uses
 thereof in therapy and drug screening
 SO Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 IN Fidock, Mark David; Robas, Nicola Melanie
 AB This invention provides protein and cDNA sequences for a newly identified
 human cyclic nucleotide phosphodiesterase, designated
 PDEXV (PDE11A3), which is believed to be a truncated
 version of PDE11A1. The invention further relates to methods
 for utilizing PDEXV in drug screening assays and in therapy
 directed against diseases assocd. with inappropriate PDEXV
 activity or levels.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1085089	A2	20010321	EP 2000-307981	20000914
	EP 1085089	A3	20010509		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001136987	A2	20010522	JP 2000-279032	20000914

(FILE 'HOME' ENTERED AT 16:51:16 ON 24 JUN 2003)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
AT 16:51:25 ON 24 JUN 2003

L1 62816 S PHOSPHODIESTERASE?
L2 591 S L1 AND PDE1? OR PDEXV
L3 242 DUP REM L2 (349 DUPLICATES REMOVED)
L4 17 S L3 AND PDE11?
L5 17 SORT L4 PY
L6 1 S L1 AND PDEXV
L7 35 S L2 AND ANTIBOD?
L8 21 DUP REM L7 (14 DUPLICATES REMOVED)
L9 21 FOCUS L8 1-
L10 9 S L9 AND PY<=1999

=> d an ti so au ab pi 16

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 2001:207980 CAPLUS

DN 134:248839

TI Protein and cDNA sequences of a novel human cyclic nucleotide
phosphodiesterase PDEXV (PDE11A3) and uses thereof in
therapy and drug screening

SO Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW

IN Fidock, Mark David; Robas, Nicola Melanie

AB This invention provides protein and cDNA sequences for a newly identified
human cyclic nucleotide **phosphodiesterase**, designated
PDEXV (PDE11A3), which is believed to be a truncated version of
PDE11A1. The invention further relates to methods for utilizing
PDEXV in drug screening assays and in therapy directed against
diseases assocd. with inappropriate **PDEXV** activity or levels.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI EP 1085089	A2	20010321	EP 2000-307981	20000914
---------------	----	----------	----------------	----------

EP 1085089	A3	20010509		
------------	----	----------	--	--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2001136987	A2	20010522	JP 2000-279032	20000914
---------------	----	----------	----------------	----------

=>